Archive
This is a library of Lhasa's blog articles.
Filter by Category
Filter by Author
- Alex Cayley
- Alex Harding
- Ally Reeves
- Alun Myden
- Anax Oliveira
- Andrew Thresher
- Ash Ali
- Cheuk Man Tsang
- Chris Barber
- Crina Heghes
- Daragh Connolly
- Dave Yeo
- David Ponting
- Emma Scrafton
- Fabrizio Campo
- Fernanda Waechter
- Grace Kocks
- Hazel Gardiner
- James McManus
- Jess Tidmarsh
- Jessica Magallanes-Castaneda
- Josh Cosby
- Kelly Gallagher
- Laura Johnston
- Liz Covey-Crump
- Martyn Chilton
- Michael Burns
- Nik Marchetti
- Oana Leonte
- Paul Imeson
- Pearl Saville
- Rachael Tennant
- Rachel Hemingway
- Raeesah Saddiq
- Rob Foster
- Sara Atkinson
- Scott McDonald
- Susanne Stalford
Filter by Product
Using existing data better and relying less on animal testing
I recently read that by 2025, 36% of world data will be healthcare data. (Yes, thirty-six percent!). Considering this statistic, now more than ever, it is important that we are working to ensure existing data is utilised to make better safety assessment decisions more quickly - whilst also relying less on animal testing.
04 August 2022
Meeting ICH S1 and reducing animal testing through AOPs; Have you read this?
“As Adverse Outcome Pathways (AOPs) move from being an interesting scientific concept, to a useful practical application tool, this is an exciting time for both industry and Lhasa” … Regular Lhasa blog readers will have read this statement within our September blog “Shaping Lhasa Limited’s scientific direction through collaboration”.
It is with great excitement that this month we can provide you with another pioneering update on the topic of our AOP work; Our paper, “Employing an adverse outcome pathway framework for weight-of-evidence assessment with application to the ICH S1B guidance addendum” has now been published in the Regulatory Toxicology and Pharmacology Journal!
03 November 2021
Shaping Lhasa Limited’s scientific direction through collaboration
“Our technology is designed by scientists, for scientists, in collaboration with industry stakeholders and regulators” …
At Lhasa Limited we often talk about the importance of industry and regulatory input in shaping our scientific direction. This article discusses a few key areas of involvement and collaboration plus, focuses on a recent example, on the topic of Adverse Outcome Pathways (AOPs). Read on to learn more and find out how you can get involved!
09 September 2021
Moving with the times; Lhasa’s cloud offerings
In a world where we are all striving for progress, technology is also advancing quickly.
Like many organisations across the life sciences industry – evidenced by the 82 Amazon Web Service (AWS) life sciences case studies - Lhasa has adopted cloud, Software as a Service (SaaS), options across three notable areas...
30 March 2021
It Takes a Team to Build an Adverse Outcome Pathway
The saying goes, “It takes a village to raise a child”. This sentiment can be translated to the work we do at Lhasa Limited, particularly to the work which we put into building Adverse Outcome Pathways (AOPs). To echo the sentiment in Chris Barber’s previous blog post, The challenge of building QSAR models; it is easy to build an AOP, harder to build a useful AOP, and as for building an AOP you can trust? It takes a team.
Read about how we are building adverse outcome pathways (AOPs) at Lhasa in this blog post written by Dr. Susanne Stalford, Senior Scientist at Lhasa.
30 September 2020
The Application of Adverse Outcome Pathways (AOPs) for Risk Assessment (A Webinar Summary)
AOPs have the potential to be very powerful for the contextualisation of alternative assays and consequently for the management of alternative testing strategies. Read about what Lhasa is doing in this area in this blog piece written by Alun Myden, Senior Scientist at Lhasa.
03 July 2020